Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.43 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | CPT2 | P23786 | 2/20 | 0.38 |
| ▸ | CPT1A | P50416 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3200657 | 1.00 | ENPP2 (0.47) | ENPP2USP30AADATSCD5TMEM97 | |
| SCHEMBL3224392 | 0.85 | ENPP2 (0.48) | ENPP2USP30AADAT | |
| SCHEMBL3219705 | 0.85 | ENPP2 (0.48) | ENPP2USP30AADAT | |
| SCHEMBL10173039 | 0.85 | ENPP2 (0.46) | ENPP2USP30AADATTMEM97SIGMAR1 | |
| SCHEMBL3220063 | 0.82 | AADAT (0.48) | ENPP2AADATTMEM97SIGMAR1PREP | |
| SCHEMBL3220048 | 0.82 | AADAT (0.48) | ENPP2AADATTMEM97SIGMAR1PREP | |
| SCHEMBL10117812 | 0.82 | AADAT (0.46) | AADATSCD5TMEM97SIGMAR1PREP | |
| SCHEMBL3215248 | 0.82 | ENPP2 (0.43) | ENPP2USP30AADATSCD5CPT1A | |
| SCHEMBL3215257 | 0.82 | ENPP2 (0.43) | ENPP2USP30AADATSCD5CPT1A | |
| SCHEMBL3219446 | 0.80 | USP30 (0.48) | USP30AADAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100055071-A1 | Anti-Viral Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20100055071-A1 | Anti-Viral Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20100055071-A1 | Anti-Viral Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| EP-2097405-A2 | ANTI-VIRAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080193411-A1 | Anti-viral Compounds | GENELABS TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080193411-A1 | Anti-viral Compounds | GENELABS TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080193411-A1 | Anti-viral Compounds | GENELABS TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008070447-A2 | ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070447-A2 | ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193411-A1 | Anti-viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | ENPP2 1731/4885USP30 4072/4885AADAT 2338/4885 |
| US-20100055071-A1 | Anti-Viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | ENPP2 1731/4885USP30 4072/4885AADAT 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.